뒤로
Cypherpunk Technologies Inc. (LPTX) 수입
LPTX 주가 차트
LPTX 수입
Cypherpunk Technologies Inc.
$0.69
19.01%
$0.11
종가: Mar 24, 16:00:00 GMT-4
$0.69
0%
$0
애프터마켓: Mar 24, 20:00:00 GMT-4
아직 데이터 없음Earnings FAQ
LPTX의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Cypherpunk Technologies Inc. LPTX의 지난 분기 매출 실적은 어땠나요?
Cypherpunk Technologies Inc.의 매출 추정치는 얼마인가요?
Cypherpunk Technologies Inc.의 수익 품질 점수는 얼마인가요?
Cypherpunk Technologies Inc.는 언제 수익을 보고하나요?
Cypherpunk Technologies Inc.의 예상 수익은 얼마인가요?
Cypherpunk Technologies Inc.은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$0.58
시가
$0.64
일일 범위
$0.61 - $0.6949
52주 범위
$0.2223 - $3.69
거래량
174.5K
평균 거래량
21.9M
배당수익률
--
EPS(TTM)
-1.58
시가총액
$39.1M
Leap Therapeutics, Inc.란 무엇인가요?
Leap Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted and immuno-oncology therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 52 full-time employees. The company went IPO on 2017-01-24. The firm is engaged in developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways. The Company’s lead clinical stage drug candidate is sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. The firm is developing DKN-01 in a clinical trial in patients with colorectal cancer and has also conducted clinical trials in patients with gastric/gastroesophageal junction cancer and endometrial cancer patients. The firm also has a preclinical program to develop a proprietary monoclonal antibody known as FL-501. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.